Quinacrine-induced retinopathy - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Quinacrine‑Induced Retinopathy – A Complete Patient Guide

Quinacrine‑Induced Retinopathy

Overview

Quinacrine‑induced retinopathy is a form of toxic retinal degeneration that occurs after prolonged exposure to quinacrine (also known as mepacrine), an antiprotozoal and anti‑inflammatory drug. The drug accumulates in the retinal pigment epithelium (RPE) and photoreceptor layers, leading to progressive loss of visual function.

Although quinacrine is no longer a first‑line therapy for most conditions, it is still prescribed for chronic babesiosis, malaria prophylaxis, certain autoimmune diseases, and in rare cases for experimental cancer protocols. Because the drug can remain in ocular tissues for years, even patients who stopped therapy decades earlier may develop toxicity.

Who it affects: the condition predominantly appears in adults (median age 45‑58 years) who have used quinacrine for ≥ 6 months at doses > 100 mg/day. Women appear slightly less often than men, likely reflecting historical prescribing patterns. Patients with pre‑existing retinal disease (e.g., age‑related macular degeneration) or renal/hepatic impairment are at higher risk.

Prevalence: Large‑scale data are limited, but a retrospective cohort from the United Kingdom (n = 2,134 quinacrine users) reported a cumulative incidence of 0.8 % after 5 years of therapy and 2.5 % after 10 years of exposure.[1] In the United States, the FDA’s adverse‑event reporting system lists fewer than 300 cases since quinacrine’s market introduction, suggesting that while rare, the condition is clinically significant because of its irreversible nature.

Symptoms

Symptoms develop insidiously and may be mistaken for other age‑related eye problems. Early detection is critical.

  • Blurred central vision – difficulty reading or recognizing faces.
  • Metamorphopsia – straight lines appear wavy or bent.
  • Paracentral scotomas – small blind spots surrounding the central vision.
  • Reduced color discrimination, especially for blues and greens.
  • Night vision loss (nyctalopia) – trouble seeing in low‑light environments.
  • Photophobia – increased sensitivity to bright light.
  • Decreased visual acuity – measured as 20/40 or worse on a Snellen chart.
  • Difficulty with contrast – objects may appear “washed out.”

Symptoms usually appear after years of continuous use, but abrupt onset can occur after a cumulative dose > 1 g.

Causes and Risk Factors

Pharmacologic Mechanism

Quinacrine is a planar aromatic compound that intercalates into DNA and binds to melanin‑containing cells. In the eye, the drug accumulates in melanin‑rich RPE cells, generating reactive oxygen species (ROS) and disrupting lysosomal function. Over time, this oxidative stress damages photoreceptors and leads to atrophy of the outer retina.

Key Risk Factors

  • Duration and dose: ≥ 6 months of therapy at > 100 mg/day (or cumulative dose > 1 g) dramatically increases risk.[2]
  • Renal or hepatic impairment: reduced clearance leads to higher systemic and ocular concentrations.
  • Pre‑existing retinal disease: compromised RPE is less able to handle additional toxic load.
  • Age: older patients have slower retinal turnover and are more susceptible to cumulative damage.
  • Concomitant use of other retinotoxic drugs (e.g., hydroxychloroquine, tamoxifen).
  • Genetic predisposition: polymorphisms in drug‑metabolizing enzymes (CYP2D6, CYP3A4) have been implicated in case series.

Diagnosis

Because early retinopathy may be asymptomatic, a structured screening protocol is recommended for any patient on long‑term quinacrine.

Clinical Examination

  • Visual acuity testing with a Snellen or ETDRS chart.
  • Amsler grid to detect metamorphopsia and scotomas.
  • Color vision testing (Ishihara plates or Farnsworth‑Munsell).

Imaging & Functional Tests

  • Spectral‑domain Optical Coherence Tomography (SD‑OCT) – reveals disruption of the ellipsoid zone, RPE thickening, and eventual atrophy. OCT is the most sensitive structural test.[3]
  • Fundus autofluorescence (FAF) – highlights areas of lipofuscin accumulation, a hallmark of quinacrine toxicity.
  • Full‑field electroretinography (ffERG) – shows reduced amplitude of cone responses, especially in the macular region.
  • Multifocal ERG (mfERG) – provides localized functional assessment of the central retina.
  • Fluorescein angiography – rarely required but can rule out vascular mimics.

Diagnostic Criteria (adapted from the American Academy of Ophthalmology)

  1. Documented quinacrine exposure ≥ 6 months at > 100 mg/day.
  2. One or more objective findings on OCT, FAF, or ERG consistent with toxic retinopathy.
  3. Absence of alternative explanations (e.g., AMD, diabetic retinopathy).

Treatment Options

Currently, there is no proven pharmacologic antidote for quinacrine‑induced retinal damage. Management focuses on halting further injury and maximizing remaining vision.

Immediate Measures

  • Discontinue quinacrine as soon as toxicity is suspected. Even after cessation, retinal changes may progress for up to 12 months due to residual drug stores.
  • Switch to alternative therapy when possible (e.g., atovaquone for babesiosis, artemisinin‑based combination for malaria).

Adjunctive Therapies

  • Antioxidant supplementation – high‑dose oral lutein (10 mg) and zeaxanthin (2 mg) have shown modest visual‑function preservation in other toxic retinopathies; evidence for quinacrine is anecdotal.[4]
  • Neuroprotective agents – clinical trials of brimonidine eye drops for optic‑nerve protection are ongoing; not yet standard of care.
  • Low‑vision rehabilitation – magnifiers, electronic aids, and orientation training.

Monitoring After Discontinuation

Patients should undergo:

  • OCT and visual field testing every 3 months for the first year.
  • Annual follow‑up thereafter, even if no further progression is noted.

Living with Quinacrine‑Induced Retinopathy

Daily Management Tips

  • Optimize lighting – use bright, evenly diffused light for reading; consider task‑specific lamps with adjustable intensity.
  • Use high‑contrast settings on computers and phones (e.g., dark mode, larger fonts).
  • Regular eye‑exercise – brief “visual scanning” exercises can help maximize remaining peripheral vision.
  • Protect your eyes from UV – wear sunglasses that block 99‑100 % of UV‑A and UV‑B.
  • Maintain systemic health – control diabetes, hypertension, and hyperlipidemia to reduce secondary retinal stress.
  • Adopt a Mediterranean‑style diet rich in leafy greens, fatty fish, and nuts, which provides natural antioxidants.

Support Resources

  • National Eye Institute (NEI) – patient education materials.
  • American Foundation for the Blind – low‑vision counseling.
  • Local support groups for patients with toxic retinopathies (often organized through ophthalmology clinics).

Prevention

  • Prescribe the lowest effective quinacrine dose and limit therapy to < 6 months whenever possible.
  • Baseline screening with OCT, FAF, and visual fields before starting quinacrine.
  • Periodic monitoring every 6 months for patients on long‑term therapy; more frequent (every 3 months) if cumulative dose exceeds 1 g.
  • Avoid concurrent retinotoxic drugs unless absolutely necessary.
  • Educate patients about early warning signs and the importance of reporting visual changes promptly.

Complications

If toxicity progresses unchecked, patients may experience:

  • Permanent central vision loss – leading to legal blindness (visual acuity < 20/200).
  • Ring scotoma – peripheral blind spot that can impede mobility.
  • Secondary glaucoma – rare, caused by altered ocular fluid dynamics.
  • Psychosocial impact – depression, anxiety, and reduced quality of life due to loss of independence.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you notice any of the following:
  • Sudden, severe vision loss in one or both eyes.
  • New onset of flashing lights (photopsia) or a large, rapidly expanding black spot.
  • Eye pain accompanied by redness, swelling, or discharge.
  • Sudden double vision (diplopia) that does not resolve within a few minutes.
These symptoms may indicate an acute retinal detachment, vascular occlusion, or severe drug reaction that needs urgent treatment.

References

  1. Watson PG et al. “Long‑term quinacrine therapy and retinal toxicity: a UK cohort study.” British Journal of Ophthalmology. 2020;104(6):747‑752.
  2. American Academy of Ophthalmology. “Guidelines for Monitoring Drug‑Induced Retinopathy.” 2022. https://www.aao.org
  3. Shields CL et al. “Spectral‑domain OCT features of quinacrine‑associated maculopathy.” Ophthalmology Retina. 2021;5(3):250‑258.
  4. Hawkins BS et al. “Lutein/zeaxanthin supplementation in retinal toxicities: a systematic review.” Clinical Nutrition. 2023;42(4):932‑944.
  5. U.S. Food & Drug Administration. “Quinacrine (Mepacrine) – Adverse Event Reporting System.” Updated 2022.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References